Patents by Inventor Patrice Cacoub

Patrice Cacoub has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF DIAGNOSIS OF INFECTION BY THE SARS-COV-2 VIRUS
    Publication number: 20230236197
    Abstract: The invention relates to a new non-invasive test making it possible to detect infection by the SARS-CoV-2 virus in a patient, using values of Apolipoprotein A1 alone or in combination with other markers.
    Type: Application
    Filed: May 26, 2021
    Publication date: July 27, 2023
    Inventors: Thierry POYNARD, Patrice CACOUB, Olivier DECKMYN
  • LOW DOSE IL-2 FOR TREATING AUTOIMMUNE-RELATED OR INFLAMMATORY DISORDERS
    Publication number: 20230149512
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Application
    Filed: January 6, 2023
    Publication date: May 18, 2023
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Assistance Publique - Hopitaux De Paris, SORBONNE UNIVERSITE
    Inventors: David KLATZMANN, David SAADOUN, Patrice CACOUB, Michèle ROSENZWAJG, Eliane PIAGGIO, Gilbert BENSIMON, Claude BERNARD
  • Use of low dose IL-2 for treating autoimmune-related or inflammatory disorders
    Patent number: 11559566
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: January 24, 2023
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
  • Use of interleukin 2 for treating Sjögren's syndrome
    Patent number: 11534479
    Abstract: The invention relates to the use of interleukin-2 in treating Sjögren's syndrome in a subject, wherein IL-2 is to be administered at a low dose of less than about 3.5 MIU/day.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: December 27, 2022
    Assignees: ILTOO PHARMA, ASSISTANCE PUBLIQUE—HÖPITAUX DE PARIS, SORBONNE UNIVERSITÉ
    Inventors: David Klatzmann, Roberta Lorenzon, Michèle Rosenzwajg, Patrice Cacoub, Arsene Mekinian
  • USE OF INTERLEUKIN 2 FOR TREATING SJÖGREN'S SYNDROME
    Publication number: 20210121532
    Abstract: The invention relates to the use of interleukin-2 in treating Sjögren's syndrome in a subject, wherein IL-2 is to be administered at a low dose of less than about 3.5 MIU/day.
    Type: Application
    Filed: February 18, 2019
    Publication date: April 29, 2021
    Applicants: ILTOO PHARMA, ASSISTANCE PUBLIQUE - HÖPITAUX DE PARIS, SORBONNE UNIVERSITÉ
    Inventors: David KLATZMANN, Roberta LORENZON, Michèle ROSENZWAJG, Patrice CACOUB, Arsene MEKINIAN
  • USE OF LOW DOSE IL-2 FOR TREATING AUTOIMMUNE-RELATED OR INFLAMMATORY
    Publication number: 20210038691
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Application
    Filed: July 10, 2020
    Publication date: February 11, 2021
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, David SAADOUN, Patrice CACOUB, Michèle ROSENZWAJG, Eliane PIAGGIO, Gilbert BENSIMON, Claude BERNARD
  • Use of low dose IL-2 for treating autoimmune—related or inflammatory disorders
    Patent number: 10765723
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: September 8, 2020
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Assistance Publique—Hopitaux De Paris, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
  • USE OF LOW DOSE IL-2 FOR TREATING AUTOIMMUNE - RELATED OR INFLAMMATORY DISORDERS
    Publication number: 20190351023
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Application
    Filed: March 22, 2019
    Publication date: November 21, 2019
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Assistance Publique - Hopitaux De Paris, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
  • Use of low dose IL-2 for treating autoimmune related or inflammatory disorders
    Patent number: 10293028
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: May 21, 2019
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Assistance Publique—Hopitaux De Paris, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michéle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
  • USE OF INTERLEUKIN 2 FOR TREATING SPONDYLOARTHRITIS
    Publication number: 20190060407
    Abstract: The invention relates to the use of interleukin-2 in treating spondyloarthritis in a human subject, wherein IL-2 is to be administered at a dose of about I to about 2 MIU/day, wherein the treatment comprises at least a first course wherein interleukin-2 is administered once per day during at least 3 consecutive days, followed by a maintenance treatment after 1 to 4 weeks.
    Type: Application
    Filed: September 9, 2016
    Publication date: February 28, 2019
    Applicants: Assistance Publique - Hôpitaux De Paris, ILTOO PHARMA, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, Francis Berenbaum, Jérémie Sellam, Bruno Fautrel, Roberta Lorenzon, Patrice Cacoub
  • USE OF LOW DOSE IL-2 FOR TREATING AUTOIMMUNE – RELATED OR INFLAMMATORY DISORDERS
    Publication number: 20170304402
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Application
    Filed: May 5, 2017
    Publication date: October 26, 2017
    Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), Assistance Publique - Hopitaux De Paris, Universite Pierre et Marie Curie (PARIS 6)
    Inventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
  • Method for stimulating T lymphocytes with IL-2
    Patent number: 9669071
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: June 6, 2017
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Assistance Publique—Hopitaux De Paris, Universite Pierre et Marie Curie (PARIS 6)
    Inventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard
  • METHOD FOR DETERMINING A PREDICTIVE FUNCTION FOR DISCRIMINATING PATIENTS ACCORDING TO THEIR DISEASE ACTIVITY STATUS
    Publication number: 20140236621
    Abstract: The invention relates to a method for determining a predictive function for discriminating patients according to their disease activity status, comprising steps of: a—measuring values of biological markers for each patient of a first group of patients having a first known disease activity status, and for each patient of a second group of patients having a second known disease activity status, the measured values forming a dataset b—analyzing the dataset for identifying biological markers which are differentially expressed between the first group of patients and the second group of patients, c—among the biological markers identified at step b, determining correlated markers as markers which are correlated with other markers above a predetermined significance level, d—removing from the dataset, values measured for a biological marker identified as correlated marker, e—analyzing the dataset obtained at step d for determining a predictive function that predicts a disease activity status of a patient as a combinat
    Type: Application
    Filed: September 26, 2012
    Publication date: August 21, 2014
    Applicants: UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Adrien Six, Wahiba Chaara, David Klatzmann, Yves Allenbach, Olivier Benveniste, Patrice Cacoub, David Saadoun, Benjamin Terrier
  • USE OF LOW DOSE IL-2 FOR TREATING AUTOIMMUNE - RELATED OR INFLAMMATORY DISORDERS
    Publication number: 20140004080
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Application
    Filed: March 9, 2012
    Publication date: January 2, 2014
    Inventors: David Klatzmann, David Saadoun, Patrice Cacoub, Michèle Rosenzwajg, Eliane Piaggio, Gilbert Bensimon, Claude Bernard